Navigation Links
ERGONEX Pharma receives Frost & Sullivan's European Orphan Diseases Entrepreneurial Company Award 2009
Date:10/19/2009

Appenzell, Switzerland, October 19, 2009 / b3c newswire / - ERGONEX Pharma received one of the prestigious European Orphan Diseases Entrepreneurial Company Award on the occasion of Frost & Sullivan's '2009 Excellence in Healthcare Awards Banquet,' held in London on 8th October 2009. The highly competitive award was presented to ERGONEX Pharma in recognition of the company's innovative therapeutic concept, its impressive display of technological know-how and targeted vision.

ERGONEX Pharma is focused on the clinical development and commercialisation of Terguride for the treatment of distinct orphan diseases. Terguride is currently being evaluated for the treatment of pulmonary arterial hypertension (PAH) in a Phase II trial in Europe and headline results are expected in 2010.

Dr. Rudolf Reiter, CEO of ERGONEX Pharma comments: "This award comes at an exciting and challenging time for ERGONEX Pharma. I see it as recognition of the vision, the commitment and work of the company, which would not have been possible without the continued support, expertise and out-of-the-box thinking of our partners in the on-going clinical trial. We believe that Terguride has the potential to contribute a new quality to emerging combination therapies for patients, who do not tolerate, have become resistant to or are insufficiently controlled by current treatment options in PAH.

The Frost & Sullivan Healthcare Awards Banquet honours Europe's best healthcare companies for their achievements over the course of this year. Frost & Sullivan's highly competitive awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development.

About Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a disorder of the blood vessels in the lung, in which the pressure in large blood vessel rises above normal. Walls of the blood vessels are thickened and hardened, becoming less elastic. Hence, the decrease in lumen leads to increases in pressure. Patients with PAH suffer from extreme shortness of breath as the heart struggles to pump against these high pressures causing such patients to ultimately die of heart failure.

About Terguride
Terguride acts as a potent antagonist on 5-HT2B and 5-HT2A receptors: It has anti-proliferative and anti-fibrotic activities and drives reverse remodelling processes. Serotonin is a signal molecule in the body with many functions. In the blood vessel walls of the lung, it stimulates proliferation of smooth muscle cells and narrowing of the blood vessels, which has been implicated in PAH. Furthermore, trophic effects of serotonin on the heart contribute to right heart hypertrophy and progression towards heart failure. Terguride is approved in Japan for hyperprolactinemia acting as a partial dopamine agonist on the pituitary gland.

About ERGONEX Pharma - www.ergonex.com
ERGONEX Pharma is a pharmaceutical company focused on developing and commercialising well-tolerated and effective products for novel and typically underserved indications. This is being achieved by forging collaborations with commercial and academic partners with expertise in the field of interest and through outsourcing activities to service providers.

Contact
ERGONEX Pharma GmbH
Ruetistr. 20
CH-9050 Appenzell
Switzerland
Phone: +41 71 788 4065
E-mail: info@ergonex.com
www.ergonex.com


'/>"/>
b3c newswire

Related biology news :

1. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
2. InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
3. Science survey ranks top biopharma employers
4. Jean-Pol Tassin wins the 2009 ECNP Neuropsychopharmacological Award
5. Researchers prolong the half-life of biopharmaceutical proteins
6. UA pharmacy research shows prescribers miss potentially dangerous drug pairs
7. 22nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey
8. 22nd Congress of the European College of Neuropsychopharmacology
9. Simulating pharmaceutical and personal care product transport
10. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
11. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... LONDON , Nov. 17, 2016 Global Market ... and Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market ... Geographical analysis for Private Biobanks shows the highest Compounded Annual ... Asia-Pacific region during the analysis period 2014-2020. ... a CAGR of 9.95% followed by Europe ...
(Date:11/14/2016)... Nov. 14, 2016  xG Technology, Inc. ("xG" or ... critical wireless communications for use in challenging operating environments, ... 30, 2016. Management will hold a conference call to ... p.m. Eastern Time (details below). Key Recent ... $16 million binding agreement to acquire Vislink Communication Systems. ...
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 02, 2016 , ... ... biotechnology companies dedicated to collaboratively developing improved chemistry, manufacturing and control technologies ... portable online UHPLC, with robust, probe-based sampling. , Online liquid chromatography ...
(Date:12/2/2016)... 1, 2016   SurePure, Inc. (OTCQB: SURP) ... the Company has concluded an agreement with Tamarack Biotics ... 90-day period to acquire units of the Company,s patented ... 3.7 million.  Concurrently with the option, ... which Tamarack will seek regulatory approvals in ...
(Date:12/2/2016)... world leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton ... HIV Self Test to 350 pharmacy representatives in Nairobi and ...
(Date:11/30/2016)... , Nov. 30, 2016  GenomOncology today announced the appointment ... of Medical Affairs.  Dr. Coleman will oversee ... company,s proprietary knowledge-enabled platform. The GenomOncology software suite empowers molecular ... sequencing data and clinical decision support, from quality control through ... , , ...
Breaking Biology Technology: